develop
effici
versatil
vivo
dendrit
cell
dc
target
vector
deliv
differ
class
antigen
protein
peptid
glycolipid
nake
dna
vaccin
applic
singl
chain
antibodi
scfv
recogn
receptor
dc
fuse
corestreptavidin
domain
express
escherichia
coli
use
express
system
bifunct
fusion
protein
bffp
express
periplasm
solubl
protein
affinitypurifi
monomer
form
bifunct
activ
biotin
character
elisa
western
blot
vivo
dc
target
divers
group
biotinyl
antigen
viral
bacteri
protein
cancer
peptid
gangliosid
dna
certain
infecti
diseas
conduct
mice
result
show
presenc
bffp
costimulatori
mab
humor
cellmedi
respons
augment
either
singl
antigen
multipl
antigen
target
strategi
lastli
bffp
base
dc
target
antigen
low
dose
may
use
strategi
design
monoval
polyval
vaccin
mass
dendrit
cell
dc
special
potent
antigen
present
cell
immun
system
dc
play
critic
role
innat
adapt
immun
respons
especi
prime
activ
cell
b
cell
immun
sever
clinic
trial
initi
human
tumor
immunotherapi
base
ex
vivo
stimul
dc
howev
clinic
respons
observ
minor
patient
procedur
costli
labori
vivo
target
dc
via
surfac
receptor
may
present
altern
simpler
rout
target
immunotherapi
dc
util
sever
surfac
receptor
integrin
fc
receptor
ctype
lectin
receptor
intern
process
present
antigen
mhc
class
mhc
class
ii
pathway
number
dc
receptor
studi
extens
antigen
target
ctype
lectin
receptor
present
immatur
matur
dc
lymphoid
tissu
lymph
node
spleen
target
antigen
antibodi
along
costimulatori
molecul
effici
strategi
achiev
protect
host
tumor
growth
reject
exist
tumor
protect
viru
airway
challeng
well
enhanc
resist
establish
rapidli
grow
tumor
viral
infect
moreov
target
singl
protein
enabl
crosspresent
sever
peptid
effici
induc
stronger
cell
immun
much
lower
dose
protein
antigen
plasmid
dna
recombin
adenoviru
absenc
costimul
target
antigen
use
suppress
develop
autoimmun
type
diabet
gener
antibodymedi
antigen
target
system
often
complex
costli
timeconsum
process
addit
requir
either
liposom
encapsul
antigen
chemic
crosslink
construct
new
hybrid
antibodi
design
may
suitabl
comparison
studi
differ
antigen
glycolipid
dna
also
vivo
target
multipl
antigen
previous
report
develop
quadroma
hybridhybridoma
base
full
length
bispecif
monoclon
antibodi
bsmab
target
biotinyl
protein
antigen
success
target
biotinyl
protein
dc
augment
immun
respons
antigen
lower
dose
howev
quadroma
express
bsmab
along
parent
unwant
heavi
light
chain
combin
furthermor
antibodybas
biotin
bind
sever
order
weaker
streptavidin
consequ
design
truncat
recombin
construct
demonstr
versatil
dc
target
vehicl
deliv
four
categori
antigen
protein
peptid
glycolipid
dna
scfv
recogn
receptor
dc
success
clone
hybridoma
fuse
truncat
corestreptavidin
domain
express
escherichia
coli
use
express
system
monomer
form
fusion
protein
affin
purifi
bifunct
activ
demonstr
elisa
western
blot
vivo
dc
target
immun
respons
studi
mice
initi
varieti
biotinyl
antigen
tabl
presenc
bffp
costimulatori
mab
humor
cellmedi
respons
estim
dc
express
mous
bone
marrow
dc
celllin
transduc
gmcsf
myc
raf
oncogen
rat
antimous
hybridoma
obtain
atcc
bsa
bovin
serum
albumin
streptavidinhrpo
horseradish
peroxidas
nhslcbiotin
biotinamidohexano
acid
ester
photobiotin
acet
ova
goat
antimousehrpo
gamhrpo
sigma
oakvil
canada
biotinyl
peptid
amino
acid
sequenc
bgvtsapdtrgvtsapdtr
ntermin
biotinyl
kindli
provid
biomira
inc
edmonton
alberta
canada
streptavidin
gene
kindli
provid
dr
sano
center
molecular
imag
diagnosi
therapi
basic
scienc
laboratori
boston
hsf
hybridoma
serum
free
media
dmem
dulbecco
modifi
eagl
medium
psg
penicillin
streptomycin
lglutamin
fb
fetal
bovin
serum
purchas
gibco
brl
burlington
canada
bbsa
biotin
n
label
bsa
prepar
biotinyl
bsa
nhslcbiotin
sigma
per
vendor
protocol
tmb
peroxidas
substrat
purchas
kirkegaard
perri
laboratori
inc
gaithersburg
md
hybond
ecl
enhanc
chemiluminisc
nitrocellulos
membran
ecl
western
blot
kit
amersham
pharmacia
biotech
baiedurf
canada
e
coli
strain
ripl
purchas
stratagen
cedar
creek
tx
mammalian
express
vector
molecular
clone
materi
modifi
restrict
enzym
mrna
isol
kit
invitrogen
burlington
canada
protein
assay
reagent
purchas
biorad
mississauga
canada
ninta
agaros
purchas
qiagen
mississauga
canada
antihi
mab
monoclon
antibodi
purchas
novagen
madison
wi
mous
interferon
gamma
elisa
enzymelink
immunosorb
assay
readysetgo
purchas
ebiosci
san
diego
ca
lal
limulu
amebocyt
lysat
pyrog
plu
singl
test
vial
purchas
cambrex
walkersvil
md
rat
antimous
mab
prepar
hybridoma
kindli
provid
dr
gold
univers
british
columbia
canada
weev
dna
encod
protein
provid
dr
l
nagata
chemic
biolog
defens
section
defens
r
canada
sarscov
membran
codon
optim
dna
purchas
geneart
ebov
dna
ebov
mammalian
express
protein
ebov
dna
encod
ebov
glycoprotein
sarscov
spike
dna
encod
sar
spike
rbd
transmembran
domain
nation
microbiolog
laboratori
winnipeg
canada
biotinyl
gangliosid
bsa
conjug
courtesi
dr
bundl
univers
alberta
canada
unpublish
data
anthrax
protect
antigen
pa
extract
slayer
recombin
caulobact
crescentu
gift
dr
j
smit
univers
british
columbia
canada
tabl
sarscov
spike
dna
sarscov
membran
dna
ebov
dna
pcr
polymeras
chain
reaction
amplifi
use
primer
respect
tabl
primer
insert
kozak
translat
initi
sequenc
initi
codon
atg
restrict
site
bamhi
ecori
pcr
fragment
gelpurifi
doubl
digest
bamhi
ecori
ligat
mammalian
express
vector
transform
cell
posit
clone
screen
restrict
digest
fragment
map
bamhi
ecori
biotinyl
use
photobiotin
acet
corestreptavidin
weev
weev
ebov
subfrag
protein
prepar
base
publish
work
ebov
sarscov
spike
rbd
membran
protein
produc
e
coli
express
system
unpublish
data
antigen
immun
label
commerci
biotin
deriv
dna
vector
biotinyl
use
photobiotin
acet
bpebov
bpsarscov
spike
bpsarscov
membran
uv
photoconjug
protein
label
nhslcbiotin
bova
bsarscov
spike
rbd
bebov
banthrax
pa
synthet
biotinyl
glycolipid
biotinyl
cancer
peptid
synthet
label
biotin
biotinyl
antigen
confirm
dot
blot
assay
probe
streptavidinhrpo
scfv
gener
hybridoma
cell
line
dna
sequenc
done
use
establish
protocol
variou
clone
design
scfv
bffp
diagrammat
shown
figur
gene
clone
differ
orient
determin
best
express
e
coli
heavi
light
chain
variabl
region
without
partial
constant
region
antibodi
amplifi
plasmid
contain
fab
dna
pcr
clone
plasmid
heavi
chain
variabl
region
gene
fuse
end
light
chain
variabl
region
gene
linker
amino
acid
constant
heavi
chain
region
sequenc
use
pcr
pcr
primer
subsequ
restrict
digestlig
method
employ
gener
v
h
v
l
scfv
gene
figur
pcr
primer
insert
restrict
site
ecori
sali
pcr
primer
insert
sali
noti
site
pcr
fragment
gelpurifi
doubl
digest
respect
insert
restrict
site
ligat
plasmid
v
l
v
h
scfv
gene
gener
method
util
pcr
primer
insert
ecori
sali
insert
sali
noti
site
light
chain
variabl
region
gene
fuse
end
heavi
chain
variabl
region
gene
via
amino
acid
constant
light
chain
sequenc
figur
scfv
orient
insert
contain
corestreptavidin
gene
orient
fusion
corestreptavidin
gene
figur
v
l
v
h
scfv
gene
fuse
terminu
corestreptavidin
gene
method
describ
figur
brief
corestreptavidin
gene
pcr
amplifi
use
primer
primer
insert
restrict
site
noti
xhoi
pcr
fragment
gelpurifi
doubl
digest
noti
xhoi
ligat
contain
v
l
v
h
scfv
gene
figur
clone
screen
character
pcr
restrict
digest
fragment
map
posit
clone
fragment
sequenc
use
promot
termin
primer
employ
posit
clone
design
follow
encod
corestreptavidinv
h
v
l
b
encod
corestreptavidinv
l
v
h
c
encod
v
l
v
h
corestreptavidin
express
scfv
bffpexpress
scfv
bffp
done
accord
previous
publish
method
scfv
bffp
gene
chemic
transform
ripl
e
coli
transform
cultur
induc
protein
express
wholecel
bacteri
pellet
analyz
western
blot
pellet
resuspend
reduc
sd
dye
mm
trishcl
ph
sd
bromophenol
blue
glycerol
mm
heat
min
prior
sdspage
pellet
electrophores
transfer
hybond
ecl
nitrocellulos
membran
use
tran
blot
apparatu
biorad
membran
block
skim
milk
probe
mous
antihi
mab
gamhrpo
reveal
ecl
accord
manufactur
protocol
bffp
gene
highest
protein
express
level
select
medium
scale
express
cultur
flask
affin
purif
perform
e
coli
periplasm
extract
use
imac
purif
protocol
describ
previous
induc
periplasm
imac
purifi
fraction
analyz
sdspage
use
polyacrylamid
gel
reduc
condit
follow
stain
coomassi
brilliant
blue
fraction
heat
min
prior
load
polyacrylamid
gel
stabil
bffpimac
purifi
bffp
heat
either
min
reduc
condit
resolv
sdspage
resolv
protein
electrophoret
transfer
onto
nitrocellulos
membran
probe
bbsa
follow
streptavidinhrpo
seed
vbottom
plate
nunc
denmark
quadrupl
cellswel
plate
wash
pb
phosphat
buffer
salin
block
pb
dialyz
bsa
remov
trace
biotin
h
incub
plate
wash
pb
bffp
ad
bind
receptor
plate
incub
h
wash
pb
bova
volum
ad
well
incub
h
incub
plate
wash
incub
streptavidinhrpo
volum
h
final
plate
wash
pb
tmb
substrat
ad
od
nm
taken
min
use
elisa
v
max
kinet
micropl
reader
molecular
devic
corp
ca
subtract
control
dc
streptavidinhrpo
incub
h
receptor
bind
specif
bffp
confirm
competit
studi
fulllength
mab
variou
concentr
mab
volum
ad
bffp
bind
full
length
mab
incub
h
allow
displac
bffp
dc
follow
wash
pb
bffp
detect
use
bova
streptavidinhrpo
tmb
mention
protocolfifteen
group
femal
balbc
mice
mice
per
group
averag
week
old
obtain
health
scienc
laboratori
anim
servic
univers
alberta
edmonton
canada
anim
treatment
care
euthanasia
carri
accord
canadian
council
anim
care
guidelin
mice
inject
subcutan
near
inguin
lymph
node
area
ml
variou
formul
antigen
bffp
salin
immun
protocol
list
tabl
three
separ
anim
experi
conduct
design
control
group
strategi
test
versatil
bffp
base
deliveri
protein
peptid
glycolipid
dna
dc
gener
immun
respons
immun
bova
perform
first
experi
group
anim
group
inject
variou
biotinyl
dna
formul
verifi
essenti
requir
dc
target
vehicl
costimulatori
molecul
group
mice
immun
bffp
without
presenc
mab
verifi
essenti
role
mab
costimul
group
mice
coimmun
mab
without
bffp
target
vector
determin
nontarget
immun
respons
group
mice
coimmun
bffp
mab
protein
antigen
deliveri
studi
group
mice
peptid
deliveri
focus
group
mice
lastli
glycolipid
antigen
investig
group
second
experi
design
confirm
versatil
nake
dna
deliveri
strategi
varieti
infecti
diseas
viral
dna
target
singl
antigen
dc
use
bffp
mediat
deliveri
system
group
ebov
dna
group
sarscov
spike
dna
group
sarscov
membran
dna
multival
immun
respons
mixtur
differ
class
antigen
studi
third
experi
group
design
evalu
multival
immun
respons
protein
peptid
bova
bebov
bsarscov
spike
rbd
banthrax
pa
immun
mixtur
salin
group
mice
coimmun
mab
corestreptavidin
without
bffp
determin
level
nontarget
immun
respons
group
mice
coimmun
bffp
without
presenc
mab
verifi
essenti
role
mab
costimul
group
mice
immun
antigen
bffp
mab
group
control
group
three
separ
anim
experi
mice
boost
concentr
antigen
categori
pb
day
follow
primari
immun
prior
immun
everi
reagent
antigen
bffp
mab
check
use
lal
pyrog
plu
singl
test
vial
kit
identifi
lipopolysaccharid
lp
contamin
endotoxin
sensit
euml
immun
reagent
premix
min
rt
prior
immun
mice
sacrif
day
boost
blood
spleen
collect
serum
isol
use
standard
procedur
use
evalu
humor
immun
respons
spleen
use
studi
ifngamma
immun
respons
spleen
differ
group
immun
mice
asept
remov
group
pool
respond
cell
isol
use
nylon
wool
column
stimul
cell
separ
group
mous
spleen
treat
mitomycin
c
previous
describ
respons
titer
measur
individu
mous
elisa
follow
immun
respect
antigen
tabl
elisa
method
done
overnight
coat
specif
antigen
nunc
elisa
micropl
volum
overnight
coat
plate
wash
pbst
tween
pb
ph
plate
block
bsa
h
rt
incub
plate
wash
pbst
dilut
serum
mous
quadrupl
ad
incub
h
rt
plate
wash
pbst
incub
gamhrpo
h
rt
h
plate
wash
pbst
tmb
ad
well
od
nm
taken
min
use
micropl
reader
activ
determin
concentr
gener
day
incub
respond
cell
cell
stimul
cell
cell
respect
antigen
ova
sarscov
spike
rbd
ebov
ebov
ebov
sarscov
spike
sarscov
spike
sarscov
spike
rbd
sarscov
membran
antigen
anthrax
pa
weev
weev
antigen
separ
incub
elisa
readysetgo
kit
use
determin
concentr
group
mice
serum
test
bbsa
bffp
corestreptavidin
use
elisa
method
serum
reactiv
determin
method
describ
section
plate
coat
either
bbsa
bffp
corestreptavidin
rest
procedur
follow
preced
section
gene
encod
fab
gener
rtpcr
tdpcr
sequenc
gener
compar
known
mab
sequenc
ncbi
blast
databas
indic
sequenc
antibodi
relat
v
l
amino
acid
sequenc
recombin
clone
ident
previou
report
howev
v
h
amino
acid
sequenc
evklvesggglvqpggslrlscaasgftfndfymnwirqppgqapewlgvirnkg
ngyttevntsvkgrftisrdntqnilylqmnslraedtaiyycarggpyyysgdda
pywgqgvmvtvss
share
homolog
v
h
amino
acid
sequenc
appear
uniqu
publish
amino
acid
sequenc
ncbi
protein
databas
wherea
amino
acid
sequenc
publish
demangel
et
al
ident
two
amino
acid
differ
termin
singl
chain
antibodi
rice
stripe
viru
protein
access
v
l
v
h
v
h
v
l
gene
success
clone
separ
plasmid
pcr
restrict
digest
dna
ligat
method
plasmid
vector
construct
insert
sequenc
encod
singlechain
antibodi
v
l
v
h
v
h
v
l
respect
next
pelb
leader
sequenc
corestreptavidin
contain
plasmid
figur
plasmid
vector
construct
insert
corestreptavidin
sequenc
v
l
v
h
scfv
contain
plasmid
figur
corestreptavidin
sequenc
nterminu
scfv
construct
wherea
corestreptavidin
ctermin
scfv
bffp
vector
transform
e
coli
cultur
induc
wholecel
bacteri
pellet
analyz
western
blot
use
antihi
mab
figur
optim
scfv
bffp
orient
express
determin
western
blot
v
l
v
h
scfv
success
express
protein
shown
desir
molecular
weight
band
either
kda
kda
figur
higher
level
protein
express
compar
therefor
subject
medium
scale
express
bffp
periplasm
space
extract
affin
purifi
imac
column
periplasm
fraction
affin
purifi
fraction
analyz
sdspage
figur
imac
purif
bffp
success
clear
band
seen
kd
affin
purifi
fraction
figur
approxim
mg
bffp
affin
purifi
l
cultur
e
coli
express
bffp
appear
isoform
monomer
dimer
tetramer
form
follow
affin
purif
either
imac
iminobiotin
column
fusion
protein
subject
size
exclus
chromatographi
isol
tetramer
fusion
protein
fusion
protein
known
heat
sensit
heat
dissoci
tetram
complet
monomer
form
tetramer
form
remain
stabl
temperatur
bffp
isoform
biotin
bind
activ
bffp
analyz
western
blot
probe
bbsa
bffp
detect
use
bbsa
streptavidinhrpo
western
blot
bffp
appear
predominantli
monomer
form
heat
either
figur
predomin
monomer
form
may
due
differ
linker
corestreptavidin
scfv
bispecif
bffp
confirm
cell
elisa
activ
demonstr
dc
cell
employ
bova
streptavidinhrpo
detect
addit
specif
receptor
bind
activ
also
confirm
competit
displac
bffp
increas
concentr
mab
figur
addit
confoc
studi
done
demonstr
dc
bind
unpublish
data
tabl
immun
protocol
describ
tabl
result
humor
cellmedi
respons
shown
figur
humor
respons
measur
antibodi
titer
immun
antigen
respect
protein
dna
vector
mous
elisa
method
magnitud
cellmedi
immun
respons
determin
amount
secret
spleen
cell
respons
antigen
spleen
cell
group
pool
averag
qualiti
data
secret
respond
cell
immun
nonimmun
mice
without
stimul
cell
minim
secret
data
shown
group
mice
divid
three
differ
experi
demonstr
abil
efficaci
dc
target
strategi
group
control
group
three
separ
anim
experi
group
immun
boost
pb
group
humor
cellmedi
immun
respons
minim
figur
group
design
demonstr
versatil
bffp
base
deliveri
distinct
class
antigen
dc
gener
immun
respons
group
mice
focus
nake
dna
deliveri
dc
verifi
essenti
requir
bffp
mab
group
mice
immun
bffp
without
presenc
mab
group
mice
coimmun
mab
without
bffp
base
target
group
mice
coimmun
bffp
mab
result
indic
group
highest
antibodi
titer
augment
secret
weev
weev
protein
compar
group
figur
immun
respons
weev
appear
higher
weev
group
immun
respons
group
minim
toward
weev
protein
antigen
probabl
due
lp
mab
bffp
effect
figur
mab
bffp
appear
essenti
dna
target
strategi
similar
immun
strategi
appli
synthet
biotinyl
peptid
glycolipid
ovalbumin
also
includ
experi
model
antigen
control
humor
respons
cellmedi
immun
respons
shown
mice
immun
protein
group
peptid
group
glycolipid
group
presenc
bffp
mab
figur
summari
result
show
mab
bffp
requir
achiev
good
immun
respons
base
dc
deliveri
dna
protein
peptid
even
gangliosid
direct
biotinyl
dna
target
dc
also
gener
strong
immun
respons
respect
dna
encod
protein
target
strategi
appli
varieti
infecti
diseas
dna
group
immun
differ
nake
dna
vector
encod
gene
differ
viral
protein
group
ebov
dna
group
sarscov
spike
dna
group
sarscov
membran
dna
pebov
encod
ebov
protein
psarscov
spike
encod
sarscov
rbd
transmembran
domain
psarscov
membran
encod
sarscov
membran
protein
strong
humor
cellmedi
respons
achiev
encod
viral
protein
target
viral
dna
dc
figur
ebov
gener
highest
immun
respons
compar
immun
respons
mammalian
express
protein
lower
e
coli
express
fragment
figur
immun
respons
ebov
rel
lower
e
coli
fragment
may
due
glycosyl
mask
epitop
signific
differ
serum
titer
sarscov
spike
protein
higher
concentr
found
sarscov
rbd
figur
group
show
minim
immun
respons
ebov
figur
group
highest
antibodi
titer
found
ova
lowest
anthrax
pa
figur
howev
highest
secret
found
anthrax
pa
figur
minim
humor
cellmedi
immun
respons
gener
group
figur
ova
immun
respons
compar
singl
antigen
multipl
antigen
target
strategi
higher
secret
serum
titer
achiev
singl
antigen
target
strategi
peptid
antigen
group
compar
multipl
antigen
target
strategi
group
figur
although
serum
titer
ova
differ
group
figur
group
higher
secret
compar
group
figur
summar
bffp
mab
requir
achiev
strong
immun
respons
protein
peptid
deliv
dc
singl
antigen
target
appear
achiev
strong
humor
cellmedi
immun
respons
comparison
multipl
antigen
target
strategi
immun
respons
shift
select
multiantigen
target
method
possibl
toward
immunodomin
antigen
serum
titer
biotin
bffp
corestreptavidin
analyz
everi
group
evalu
immunogen
bffp
target
vehicl
ident
concentr
bffp
corestreptavidin
coat
onto
plate
serum
reactiv
found
extent
corestreptavidin
od
bffp
od
howev
level
serum
reactiv
differ
compar
control
group
figur
serum
reactiv
toward
bbsa
minim
group
od
vivo
target
dc
receptor
shown
effect
gener
immun
respons
protect
host
cancer
viral
infect
autoimmun
diseas
four
type
target
system
report
thu
far
includ
scfv
coat
liposom
b
chemic
crosslink
antigen
c
hybrid
antibodi
bsmab
target
system
sever
limit
seen
system
current
strategi
demonstr
effici
deliveri
peptid
protein
dc
deliveri
system
may
versatil
flexibl
enough
clinic
applic
comparison
studi
differ
antigen
vivo
target
multipl
antigen
dna
glycolipid
limit
scfv
coat
liposom
target
strategi
includ
instabl
scfv
liposom
surfac
scfv
could
lost
circul
liposom
instabl
scaleup
issu
rel
complex
encapsul
process
certain
class
antigen
encapsul
effici
addit
issu
includ
batch
batch
variat
crosslink
purif
fc
domain
mediat
effect
limit
chemic
crosslink
whole
mab
antigen
hybrid
antibodi
recombin
antigen
fusion
protein
gener
use
mammalian
express
system
labor
intens
requir
care
monitor
cell
product
posttransl
chemic
modif
degrad
aggreg
final
product
furthermor
new
antibodi
fusion
protein
requir
antigen
protein
peptid
process
often
timeconsum
costli
bsmab
produc
quadroma
ideal
clinic
applic
limit
includ
yield
puriti
major
disadvantag
system
could
doselimit
toxic
prolong
circul
time
immunogenc
target
system
alter
pharmacokinet
biodistribut
clearanc
block
receptorantigen
interact
induc
hypersensit
reaction
inject
site
reaction
consequ
truncat
monomer
singlechain
antibodycorestreptavidin
fusion
protein
bffp
form
complex
biotinyl
antigen
k
one
paratop
deliv
antigen
dc
via
receptor
second
paratop
may
desir
altern
vivo
dc
target
system
sever
uniqu
properti
target
system
almost
class
antigen
biotinyl
chemic
conjug
instanc
nhslcbiotin
photoactiv
photobiotin
acet
incorpor
synthet
strategi
biotinyl
avoid
need
encapsul
chemic
crosslink
construct
new
hybrid
fusion
antibodi
bffp
lack
fc
domain
e
coli
base
product
consist
econom
faster
clearanc
rate
kidney
glomerular
filtrat
cutoff
kda
lower
immunogen
expect
due
smaller
molecular
weight
kda
vector
requir
bffp
stabil
halflif
increas
polyethylen
glycol
linkag
isol
tetramer
form
bffp
moreov
target
vehicl
translat
clinic
applic
commun
develop
versatil
bffp
bind
biotinyl
antigen
target
dc
receptor
use
recombin
antibodi
technolog
receptor
bind
specif
also
confirm
via
competit
bind
replac
bffp
full
length
mab
studi
vivo
studi
mice
biotinyl
dna
weev
ebov
sarscov
spike
sarscov
membran
protein
ova
peptid
glycolipid
shown
presenc
bffp
mab
costimul
humor
cellmedi
respons
augment
multipl
antigen
target
strategi
also
achiev
humor
cellmedi
respons
ova
sarscov
spike
rbd
anthrax
pa
antigen
administ
low
dose
ng
dc
target
strategi
respect
data
vivo
fluoresc
imag
would
decis
establish
specif
vivo
target
propos
futur
antigen
spare
strategi
import
pandem
diseas
manag
larg
popul
need
vaccin
made
theoret
calcul
suggest
event
sar
avian
influenza
outbreak
canada
dc
target
vaccin
need
cover
subject
requir
g
ng
dose
vaccin
antigen
comparison
recent
commerci
influenza
vaccin
clinic
trial
use
modest
immun
respons
requir
kg
antigen
specul
dc
target
effici
deliv
antigen
dc
convent
subcutan
vaccin
could
encount
prolong
exposur
enzym
uptak
none
dc
cell
anoth
import
applic
deliveri
multipl
pathogen
antigen
combin
vaccin
could
provid
suffici
protect
first
emerg
respond
biodefens
applic
summari
dc
target
approach
achiev
strong
immun
respons
class
antigen
singl
antigen
target
exhibit
strong
humor
cellmedi
immun
respons
comparison
multiantigen
target
strategi
like
exhibit
immun
respons
shift
toward
immunogen
antigen
higher
immun
respons
achiev
weak
immunogen
ova
singl
antigen
target
strategi
compar
multival
strategi
also
demonstr
target
bioterror
agent
dna
ebov
sarscov
spike
weev
structur
dna
induc
strong
humor
cellmedi
immun
respons
dna
encod
protein
target
formul
low
concentr
biotinyl
dna
ng
salin
adequ
achiev
strong
immun
respons
mice
contrast
convent
dna
vaccin
therapi
strategi
often
requir
high
concentr
multipl
immun
effici
induc
immun
respons
importantli
wide
use
experiment
viral
vector
base
gene
target
strategi
caus
sever
advers
sideeffect
includ
death
specul
absenc
viral
vector
nake
biotinyl
dna
target
could
safer
altern
vitro
vivo
neutral
studi
sarscov
ebov
challeng
studi
weev
progress
immun
respons
toward
either
hapten
biotin
bbsa
carrier
bffp
minim
mitig
deimmun
strategi
slight
reactiv
toward
bffp
appear
corestreptavidin
portion
fusion
protein
bffp
target
biotinyl
antigen
dc
could
conveni
versatil
method
deliv
singl
multipl
antigen
dc
formul
could
induc
immun
respons
toward
peptid
protein
glycolipid
dna
vaccin
base
express
product
bffp
target
dc
may
potenti
candid
develop
vaccin
therapi
cancer
bioterror
agent
weev
ebov
sarscov
anthrax
translat
vivo
target
strategi
human
like
complex
sinc
receptor
human
may
also
target
b
cell
nk
cell
cell
monocyt
thymic
epitheli
cell
addit
multipl
immun
may
requir
achiev
adequ
immun
respons
human
fact
even
mous
model
bffp
inject
follow
nontarget
booster
dose
analysi
humor
immun
respons
biotinyl
antigen
vivo
group
five
mice
immun
differ
antigen
combin
along
pb
control
specif
compon
amount
schedul
immun
outlin
tabl
mice
analyz
individu
data
pool
humor
respons
quantifi
serum
antibodi
titer
day
post
immun
measur
elisa
method
respect
antigen
shown
xaxi
list
tabl
method
involv
coat
antigen
microtit
plate
follow
addit
dilut
serum
antibodi
detect
use
gamhrpo
elisa
measur
done
quadrupl
mous
mean
elisa
valu
obtain
individu
mous
averag
error
bar
repres
standard
deviat
group
mice
tabl
isol
purifi
use
nylon
wool
column
five
spleen
group
pool
mix
dmem
prior
nylon
wool
purif
stimul
cell
prepar
mice
spleen
cell
isol
treat
mitomycin
c
purifi
respond
cell
immun
nonimmun
mice
analysi
serum
reactiv
toward
biotin
bffp
corestreptavidin
mice
mice
per
group
analyz
individu
data
pool
mous
group
list
xaxi
correspond
tabl
group
control
group
pb
immun
group
immun
presenc
absenc
bffp
accord
tabl
serum
reactiv
quantifi
serum
antibodi
titer
day
post
immun
measur
elisa
method
bbsa
bffp
corestreptavidin
shown
figur
legend
method
involv
coat
ml
antigen
shown
figur
legend
microtit
plate
follow
addit
dilut
serum
antibodi
detect
use
gamhrpo
elisa
measur
done
quadrupl
mous
mean
elisa
valu
obtain
individu
mous
averag
error
bar
repres
standard
deviat
group
mice
immun
protocol
evalu
humor
cellmedi
immun
respons
biotinyl
antigen
mice
n
